Xentria
Business Services · Illinois, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
8700 W Bryn Mawr Ave Ste 600S, Chicago, ...Phone Number
(224) 443-4615Website
www.xentria.comRevenue
$9.6 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Xentria
Xentria is a biotech company focused on building authentic life-sciences partnerships to facilitate innovative drug and intellectual property development from initial concepts through clinical trials to commercial launch. The company is currently researching treatments for pulmonary sarcoidosis, specifically through its investigational drug XTMAB-16. Xentria aims to reinvent life-sciences partnerships to enhance drug innovation and improve patient outcomes. Their services cater to ambitious developers facing challenging drug projects, guiding them through the complexities of drug development.Explore more
Xentria Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Xentria your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Xentria had a recent Job posting/layoffs
Xentria, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Xentria launches new products
Check out if Xentria is spiking on competitors!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Xentria recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Xentria has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Xentria
Funding: Get notified immidiatlly once Xentria has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Xentria
Compare insights from companies similar to Xentria, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Xentria is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Xentria is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Xentria.
Xentria financials insights
Gather financial insights about Xentria, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Private Equity
$25M
Xentria Tech Stack
A closer look at the technologies used by Xentria
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Partnership
Partnership, Research & Development, Product Management, Intellectual Property, Legal Affairs, Medical Research, Pharmaceuticals
Event
Events
Open Position
Xentria News & Media
Expanding Horizons: Xentria Achieves Milestone Success with Biosimilar Development
Xentria announces operational milestone with expansion of multiple clinical trials in 11 countries and 3 regions across their portfolio. Advancements in operational infrastructure allows for further portfolio growth to develop therapeutics and address unmet medical needs. CHICAGO, Jan. 8,...Xentria Announces Exclusive Licensing Agreement with New York University to Advance a Disease-Modifying Cardiovascular Therapy Globally
- Exclusive rights secured related to the development of a potential disease-modifying therapeutic for cardiovascular disease. CHICAGO, Dec. 19, 2024 /PRNewswire/ -- Xentria, Inc. (Xentria), a clinical-stage biotherapeutics company focused on advancing drug development to address unmet...Xentria’s XTMAB-16 Receives Orphan Drug Designation From European Medicines Agency as First Patient is Enrolled in Study
CHICAGO--(BUSINESS WIRE)--Xentria, Inc., a clinical-stage biotherapeutics company focused on developing therapeutics to address unmet clinical needs, today announced that its lead candidate, XTMAB-16, has been granted Orphan Drug Designation by the European Medicines Agency (EMA). The company is also announcing that the first US patient has been enrolled in its global study to evaluate XTMAB-16 as treatment for the rare disease sarcoidosis. Xentria is developing XTMAB-16, an anti-TNFα monoclonaXentria and Meitheal Pharmaceuticals Announce Exclusive Licensing Agreement for XTMAB-16 in North America
CHICAGO--(BUSINESS WIRE)--Xentria and Meitheal Pharmaceuticals Announce Exclusive Licensing Agreement for XTMAB-16 in North America
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Xentria
Sign Up For FreeTo access detailed company insights
Xentria is a biotech company focused on building authentic life-sciences partnerships to facilitate innovative drug and intellectual property development from initial concepts through clinical trials to commercial launch. The company is currently researching treatments for pulmonary sarcoidosis, specifically through its investigational drug XTMAB-1... Read More
